Chronic Hepatitis C
Studies add new findings to chronic hepatitis c body of knowledge
Published in Hepatitis Weekly, July 25th, 2005
Study 1: Combined therapy improves ALT levels in patients with hepatitis C genotype 1.
"The possibility of delaying progression to hepatocellular carcinoma in chronic hepatitis C patients with genotype 1 and high viral titers with baseline alanine aminotransferase (ALT) levels of {{>=}}50 IU/L was examined by administration of interferon (IFN) plus ribavirin combination therapy using ALT normalization as index and IFN monotherapy as control," scientists in Japan report.
"The rate of sustained ALT normalization (ALT normal at 24 weeks after the end of treatment)...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-07-25)
More Articles from Hepatitis Weekly
- Chronic Liver Disease
Three dimensional software enriches liver resection and transplantation - Endocrinology
Patients treated for chronic hepatitis C may develop thyroid dysfunction - Hepatitis B Vaccine
Non-invasive niosomes offer topical immunization against hepatitis B - Obstetrics
Immunological status influences hepatitis E severity in pregnant women - Transplant Medicine
Repeated pulse therapy increases graft loss in HCV-positive liver recipients - Allergy and Immunology
Lymphatic tissue does not support hepatitis B replication in carriers - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
